HK1156696A1 - Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway - Google Patents

Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway

Info

Publication number
HK1156696A1
HK1156696A1 HK11110985.3A HK11110985A HK1156696A1 HK 1156696 A1 HK1156696 A1 HK 1156696A1 HK 11110985 A HK11110985 A HK 11110985A HK 1156696 A1 HK1156696 A1 HK 1156696A1
Authority
HK
Hong Kong
Prior art keywords
selection
treatment
colorectal cancer
cancer patients
drugs targeting
Prior art date
Application number
HK11110985.3A
Other languages
English (en)
Inventor
Heinrich Roeder
Maxim Tsypin
Julia Grigorieva
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Publication of HK1156696A1 publication Critical patent/HK1156696A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Computing Systems (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Software Systems (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Theoretical Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
HK11110985.3A 2009-01-20 2011-10-14 Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway HK1156696A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/321,394 US7858390B2 (en) 2006-03-31 2009-01-20 Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
PCT/US2009/006267 WO2010085234A1 (fr) 2009-01-20 2009-11-20 Sélection de patients souffrant de cancers colorectaux en vue de traitements par des médicaments ciblant la voie egfr

Publications (1)

Publication Number Publication Date
HK1156696A1 true HK1156696A1 (en) 2012-06-15

Family

ID=41571343

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11110985.3A HK1156696A1 (en) 2009-01-20 2011-10-14 Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway

Country Status (11)

Country Link
US (1) US7858390B2 (fr)
EP (1) EP2347261B1 (fr)
JP (1) JP4997345B2 (fr)
KR (1) KR101131231B1 (fr)
AU (1) AU2009338173B2 (fr)
CA (1) CA2744394A1 (fr)
ES (1) ES2392805T3 (fr)
HK (1) HK1156696A1 (fr)
IL (1) IL211944A (fr)
TW (1) TWI366671B (fr)
WO (1) WO2010085234A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
KR101556726B1 (ko) * 2010-02-24 2015-10-02 바이오디식스, 인크. 질량스펙트럼 분석을 이용한 치료제 투여를 위한 암 환자 선별
JP2014505257A (ja) 2011-01-28 2014-02-27 バイオデシックス・インコーポレイテッド ホルモン療法および組み合わせ療法のための転移性乳癌患者の選択の予測試験
EP2864792A1 (fr) 2012-06-26 2015-04-29 Biodesix, Inc. Procédé par spectre de masse pour sélectionner des patients et annuler la sélection de patients atteints de cancer pour un traitement avec des thérapies de génération de réponse immunitaire
CA2878441A1 (fr) 2012-07-05 2014-01-09 Biodesix, Inc. Procede permettant de prevoir si un patient ne tirera pas profit d'agents de chimiotherapie a base de platine
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
US10007766B2 (en) 2015-07-13 2018-06-26 Biodesix, Inc. Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
AU2017210338B2 (en) 2016-01-21 2021-08-05 Protein Dynamic Solutions Inc. Method and system for spectral data analysis
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
US11621057B2 (en) 2016-04-08 2023-04-04 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
EP3566054A4 (fr) 2017-01-05 2020-12-09 Biodesix, Inc. Procédé d'identification de patients cancéreux susceptibles de tirer durablement profit d'une immunothérapie dans des sous-groupes de patients présentant, de façon générale, un mauvais pronostic
JP2021508104A (ja) 2017-12-15 2021-02-25 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1540010T3 (da) 2002-08-06 2010-07-26 Univ Johns Hopkins Anvendelse af biomarkører til påvisning af ovariecancer
AU2004248140A1 (en) 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
US20050267689A1 (en) 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
US20050048547A1 (en) 2003-07-17 2005-03-03 Hongyu Zhao Classification of disease states using mass spectrometry data
JP2007531879A (ja) 2004-03-30 2007-11-08 イースタン バージニア メディカル スクール 肺癌バイオマーカー
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
PL1913157T5 (pl) * 2005-06-28 2017-09-29 Genentech Inc Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR
WO2007109571A2 (fr) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Procédés de prédiction et de suivi de la thérapie par l'inhibiteur de la tyrosine kinase
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway

Also Published As

Publication number Publication date
IL211944A0 (en) 2011-06-30
US20090170216A1 (en) 2009-07-02
IL211944A (en) 2014-01-30
CA2744394A1 (fr) 2010-07-29
ES2392805T3 (es) 2012-12-14
TW201028687A (en) 2010-08-01
EP2347261B1 (fr) 2012-08-15
US7858390B2 (en) 2010-12-28
JP2012507033A (ja) 2012-03-22
KR101131231B1 (ko) 2012-03-28
WO2010085234A1 (fr) 2010-07-29
TWI366671B (en) 2012-06-21
JP4997345B2 (ja) 2012-08-08
AU2009338173B2 (en) 2012-02-16
EP2347261A1 (fr) 2011-07-27
AU2009338173A1 (en) 2010-07-29
KR20110061605A (ko) 2011-06-09

Similar Documents

Publication Publication Date Title
TWI366671B (en) Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway
IL219073A (en) A drug combination for cancer treatment
IL218575A0 (en) Treatment of cancer
IL216913A0 (en) Targeted nano-photomedicines for photodynamic therapy of cancer
ZA201300218B (en) Treatment of blood cancer
EP2557923A4 (fr) Traitement de cancers présentant des mutations k-ras
SG10201508495VA (en) Combination treatment of cancer
EP2470200A4 (fr) Immunogènes cytotoxiques induisant des lymphocytes t pour prévenir, traiter et diagnostiquer un cancer
EP2539704A4 (fr) Sélection de patient cancéreux pour l'administration d'agents thérapeutiques utilisant une analyse par spectrométrie de masse
EP2373794A4 (fr) Nectine-4 pour gènes cibles de thérapie contre le cancer et de diagnostic du cancer
EP2788752A4 (fr) Procédé de sélection d'un traitement destiné à des patients souffrant d'un cancer
EP2606349A4 (fr) Diagnostic du cancer et agent thérapeutique anticancéreux
IL207046A (en) Quinazoline derivatives for the treatment of cancer-related disorders
EP2509421A4 (fr) Administration d'un médicament, le témozolomide, dans le cadre d'un traitement systémique du cancer
EP2398901A4 (fr) Jarid1b en tant que gène cible d'un traitement anticancéreux et d'un diagnostic de cancer
SG10201608967WA (en) Cancer stem cell-targeted and drug resistant cancer therapy
PL388252A1 (pl) Terapia skojarzona raka jelita grubego
ZA201202169B (en) Targeting pax2 for the treatment of breast cancer
EP2619331A4 (fr) Méthodes de traitement du cancer comportant le ciblage de nqo1
EP2473613A4 (fr) Thérapie de privation de cancer
EP2350276A4 (fr) Syngr4 pour gènes cibles du traitement et du diagnostic du cancer
GB0916686D0 (en) Treatment of cancer
HK1145979A1 (en) Production of an homogeneous vaccine preparation for cancer treatment
EP2576610A4 (fr) Biomarqueur pour le diagnostic et le traitement du cancer colorectal
EP2262541A4 (fr) C2orf18 comme gène cible d'une thérapie et d'un diagnostic du cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161120